WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced key presentations that will be featured during a CME symposium at the Amputation Prevention (AMP) Conference in Chicago on August 8.
The symposium, titled “Why Dissections Matter: A case-based look at below-the-knee lesions post-PTA” will explore how post-percutaneous transluminal angioplasty (PTA) dissections are often overlooked, underdiagnosed and left untreated. These dissections can compromise clinical outcomes in both the short and long term, thus putting limbs at increased risk of reduced blood flow, gangrene and amputation. The symposium will feature three critical limb ischemia experts: George Adams, MD, Marianne Brodmann, MD and Peter Soukas, MD.
“The effect of post-angioplasty dissection in lower extremities, or below-the-knee, is particularly detrimental in patients with critical limb ischemia,” said George Adams, M.D., M.H.S., Director of Cardiovascular and Peripheral Vascular Research, UNC REX Hospital, Raleigh, N.C. “The ability to properly identify and treat these dissections is essential to preserving blood flow and preventing amputation in this vulnerable patient population.”
Intact Vascular’s Tack Endovascular System® is a new solution for precision dissection repair following balloon angioplasty with a first-of-its-kind implant that is designed to help maintain vessel integrity and enhance blood flow to promote healing, improve outcomes and preserve limbs. The Tack Endovascular System leaves a minimal amount of metal in the artery, reduces mechanical stress on the arterial wall and preserves future treatment options.
Intact Vascular is sponsoring three clinical trials to evaluate its Tack Endovascular System: TOBA II, TOBA II BTK and TOBA III. TOBA II is investigating the combination of the Tack implant with both plain angioplasty balloons and the BARD Lutonix® drug-coated balloon (DCB) in the arteries above the knee, and completed enrollment in March 2017. TOBA II BTK is investigating the combination of the Tack implant with plain balloon angioplasty in the arteries below the knee and is actively enrolling patients. TOBA III has completed enrollment in Europe and is investigating the combination of the Tack implant with the Medtronic IN.PACT™ Admiral™ (DCB), inclusive of long lesions.
About Intact Vascular
Intact Vascular is a privately held medical device company that develops minimally- invasive peripheral vascular products. The Tack Endovascular System is designed to improve peripheral balloon angioplasty results in the treatment of peripheral arterial disease. Visit www.intactvascular.com for more information.
This press release contains “forward-looking statements” concerning the development of Intact Vascular’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Intact Vascular undertakes no obligation to update any forward-looking statements for any reason.
Tack Endovascular System® is a trademark of Intact Vascular, Inc.
Lutonix® is a trademark of C.R. BARD, Inc.
IN.PACT(TM) Admiral(TM) are trademarks of Medtronic.
“CAUTION: Investigational device. Limited by Federal (United States) law to investigational use.”
The Tack Endovascular System® is CE Mark Authorized under EC Directive 93/42/EEC.
Not available for sale or use in the United States.
Intact Vascular, Inc.
Andrea Dunkle, 1-484-253-1048